Nanoliposome-based malvidin or N-acetylcysteine therapeutics for attenuating mitochondrial dysfunction in Alzheimer’s disease: a targeted strategy

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, and neuronal impairment. Natural antioxidants such as malvidin and N-acetylcysteine (NAC) exhibit antioxidant and anti-inflammatory properties, thereby help reduce reactive oxygen species (ROS) and support cellular redox balance by strengthening endogenous antioxidant defenses under conditions of oxidative stress and inflammation. By concurrently targeting oxidative stress, mitochondrial dysfunction, and neuroinflammation, these compounds could be promising candidates as multi-pathway metabolic stabilizers capable of mitigating AD pathology. Nonetheless, the therapeutic efficacy of such bioactive compounds is frequently constrained by their poor stability, rapid degradation, lower bioavailability and inefficient delivery to target tissues. Nanoliposome-based delivery systems can address these limitations by offering enhanced biocompatibility, improved stability, and efficient site-specific delivery of vulnerable bioactive compounds. This review summarizes the molecular mechanisms underlying mitochondrial dysfunction in AD, examines the individual neuroprotective effects of malvidin and NAC, and highlights the rational and emerging potential of malvidin-loaded and NAC-loaded nanoliposomes as two distinct targeted strategies for attenuating mitochondrial dysfunction in AD. This distinction provides a framework for considering each compound as an independent candidate for further investigation in AD-related therapeutic research.

Authors

Institutions

Publication Details

Journal
Frontiers in Genetics
Published
2026-11-19
DOI
https://doi.org/10.3389/fgene.2026.2002211
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nanoliposome-based malvidin or N-acetylcysteine therapeutics for attenuating mitochondrial dysfunction in Alzheimer’s disease: a targeted strategy

Vijay K. Hegde, Most Arifa Sultana
2 links
Frontiers in Genetics
Alzheimer's disease research and treatments
article

Nanoliposome-based malvidin or N-acetylcysteine therapeutics for attenuating mitochondrial dysfunction in Alzheimer’s disease: a targeted strategy

Vijay K. Hegde, Most Arifa Sultana
article en

Abstract

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, and neuronal impairment. Natural antioxidants such as malvidin and N-acetylcysteine (NAC) exhibit antioxidant and anti-inflammatory properties, thereby help reduce reactive oxygen species (ROS) and support cellular redox balance by strengthening endogenous antioxidant defenses under conditions of oxidative stress and inflammation. By concurrently targeting oxidative stress, mitochondrial dysfunction, and neuroinflammation, these compounds could be promising candidates as multi-pathway metabolic stabilizers capable of mitigating AD pathology. Nonetheless, the therapeutic efficacy of such bioactive compounds is frequently constrained by their poor stability, rapid degradation, lower bioavailability and inefficient delivery to target tissues. Nanoliposome-based delivery systems can address these limitations by offering enhanced biocompatibility, improved stability, and efficient site-specific delivery of vulnerable bioactive compounds. This review summarizes the molecular mechanisms underlying mitochondrial dysfunction in AD, examines the individual neuroprotective effects of malvidin and NAC, and highlights the rational and emerging potential of malvidin-loaded and NAC-loaded nanoliposomes as two distinct targeted strategies for attenuating mitochondrial dysfunction in AD. This distinction provides a framework for considering each compound as an independent candidate for further investigation in AD-related therapeutic research.

Frontiers in GeneticsVol. 17
Texas Tech University (US), Texas Tech University Health Sciences Center (US)
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon